The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071
Nanda, R., Liu, M. C., Yau, C., Shatsky, R., Pusztai, L., Wallace, A., Chien, A. J., Forero-Torres, A., Ellis, E., Han, H., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.6650 · Cited by 710
Cortes, J., Cescon, D. W., Rugo, H. S., Nowecki, Z., Im, S.-A., Yusof, M. M., Gallardo, C., Lipatov, O., Barrios, C. H., Holgado, E., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.1000 · Cited by 186
Cited by
Gennari, A., André, F., Barrios, C. H., Cortés, J., de Azambuja, E., DeMichele, A., Dent, R., Fenlon, D., Gligorov, J., Hurvitz, S. A., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.019 · Cited by 1,417
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs
Bianchini, G., De Angelis, C., Licata, L., & Gianni, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00565-2 · Cited by 1,382
A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer
Bassez, A., Vos, H., Van Dyck, L., Floris, G., Arijs, I., Desmedt, C., Boeckx, B., Vanden Bempt, M., Nevelsteen, I., Lambein, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01323-8 · Cited by 867
Breast Cancer Treatments: Updates and New Challenges
Burguin, A., Diorio, C., & Durocher, F. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080808 · Cited by 488
Immunotherapy in breast cancer: an overview of current strategies and perspectives
Debien, V., De Caluwé, A., Wang, X., Piccart-Gebhart, M., Tuohy, V. K., Romano, E., & Buisseret, L. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00508-3 · Cited by 368
Metadata
- Authors
- Bachelot, T., Filleron, T., Bieche, I., Arnedos, M., Campone, M., Dalenc, F., Coussy, F., Sablin, M.-P., Debled, M., Lefeuvre-Plesse, C., Goncalves, A., Reynier, M.-A. M., Jacot, W., You, B., Barthelemy, P., Verret, B., Isambert, N., Tchiknavorian, X., Levy, C., Thery, J.-C., L’Haridon, T., Ferrero, J.-M., Mege, A., Del Piano, F., Rouleau, E., Tran-Dien, A., Adam, J., Lusque, A., Jimenez, M., Jacquet, A., Garberis, I., & Andre, F.
- Venue
- Nature Medicine
- Published
- 2021-01-18
- Volume
- 27
- Issue
- 2
- Pages
- 250-255
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W3121740707
- Cited by
- 161
- References
- 4
- FWCI
- 9.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial. https://app.cochat.ai/papers/10.1038/s41591-020-01189-2
- The paper
- Bachelot, T., Filleron, T., Bieche, I., Arnedos, M., Campone, M., Dalenc, F., Coussy, F., Sablin, M.-P., Debled, M., Lefeuvre-Plesse, C., Goncalves, A., Reynier, M.-A. M., Jacot, W., You, B., Barthelemy, P., Verret, B., Isambert, N., Tchiknavorian, X., Levy, C., . . . Andre, F. (2021). Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial. Nature Medicine. https://doi.org/10.1038/s41591-020-01189-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.